Barclays PLC Protalix Bio Therapeutics, Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 126,963 shares of PLX stock, worth $271,700. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,963
Previous 126,963
-0.0%
Holding current value
$271,700
Previous $188,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PLX
# of Institutions
69Shares Held
8.7MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$3.46 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$2.31 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.77 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$1.06 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$1.04 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $106M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...